References
- NIH Concensus Development Panel on osteoporosis, JAMA 2001.
- Jackson J A. Osteoporosis in men. Primer on the metabolic bone diseases and disorders of mineral metabolism, M J Favus. Lippincott-Raven, Philadelphia 1993; 255–258
- Bilezikian J P. Osteoporosis in men. J Clin Endocrinol Metab 1999; 84: 3431–3434
- Chesnut C H, Silverman S, Andriano K, Genant H, Gimano A, Harris S, et al. A randomised trial of nasal salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 2000; 109: 267–276
- O'Neill T W, Felsenberg D, Varlow J, Cooper C, Kanis J A, Silman A J. The prevalence of vertebral deformity in European men and women: The European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11: 1010–1218
- Center J R, Nguyen T V, Schneider D, Sambrook P N, Eisman J A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878–882
- Black D M, Thompson D E, Bauer D C, Ensrud K, Musliner T, Hochberg M C, Nevitt M C, Suryawanshi S, Cummings S R, Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85: 4118–4124
- Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604–610
- Ho Y V, Frauman A G, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporosis Int 2000; 11: 98–101
- Ringe J D, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two arm study. Rheum Int 2004; 24: 110–113
- Trovas G P, Lyritis G P, Galanos A, Raptou P, Constantelou E. A randomized triaal of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002; 17: 521–527
- Weber T J, Drezner M K. Effect of alendronate on bone mineral density in male idiopathic osteoporosis. Metabolism 2001; 50: 912–915
- Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, Gennari L, Gennari C, Nuti R. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 2003; 73: 133–139
- Toth E, Csupor E, Meszaros S, Ferenz V, Nemeth L, McCloskey E V, Horvath C. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures-an open label study. Bone 2005; 36: 47–51